Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI-generated claim accurately reflects the boxed warning and related labeling (Sections Boxed Warning, 5.1, 8.4, and 17) regarding increased risk of suicidal thoughts/behaviors in pediatric and young adult patients and the need for close monitoring and counseling, with no contradictions or missing material safety elements.
Category Scores
Accurate Statements
Medically relevant warning: Sertraline (antidepressants/SSRIs) increases the risk of suicidal thoughts and behaviors in pediatric and young adult patients, and patients should be closely monitored and counseled accordingly.
Supported by Boxed Warning (increased risk in pediatric and young adult patients; closely monitor; [see 5.1]), Section 5.1 (monitor all antidepressant-treated patients; especially early and with dose changes; consider changing/discontinuing if persistent worsening or emergent suicidality), Pediatric Use 8.4 (monitor for clinical worsening, suicidal thoughts, unusual behavior changes; especially early and with dose changes), and Patient Counseling 17 (advise patients/caregivers to look for emergent suicidality, especially early and when dosage adjusted).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim aligns with labeled warnings and includes the key safety actions emphasized in the label (close monitoring and counseling for emergence of suicidality, especially early and with dose changes).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement